[{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"intravitreal implant","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ SWK Holdings Corporation","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ Ocumension Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ Ocumension Therapeutics"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"PLA2","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"SIFI","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ SIFI","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ SIFI"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Horus Pharma","sponsor":"Alimera Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Horus Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Horus Pharma \/ Alimera Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Horus Pharma \/ Alimera Sciences"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Alimera Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.080000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Alimera Sciences","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ Alimera Sciences"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0.38,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.38,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Eclipse Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eclipse Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eclipse Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eclipse Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0.38,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0.38,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ ANI Pharmaceuticals Inc"}]

Find Clinical Drug Pipeline Developments & Deals for Fluocinolone Acetonide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Upon acquisition ANI will inherit Iluvien (fluocinolone acetonide), a drug used to treat diabetic macular oedema & recurrent non-infectious posterior uveitis in the US, Europe and Middle East.

                          Brand Name : Iluvien

                          Molecule Type : Small molecule

                          Upfront Cash : $381.0 million

                          September 16, 2024

                          Lead Product(s) : Fluocinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : ANI Pharmaceuticals Inc

                          Deal Size : $381.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Upon acquisition ANI will inherit Iluvien (fluocinolone acetonide), a drug used to treat diabetic macular oedema & recurrent non-infectious posterior uveitis in the US, Europe and Middle East.

                          Brand Name : Iluvien

                          Molecule Type : Small molecule

                          Upfront Cash : $381.0 million

                          September 11, 2024

                          Lead Product(s) : Fluocinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : ANI Pharmaceuticals Inc

                          Deal Size : $381.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          Eclipse Life Sciences

                          Country arrow
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Eclipse Life Sciences

                          Country arrow
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : EC-104 (fluocinolone acetonide) extended release, a novel intravitreal corticosteroid implant is being investigated for the treatment of diabetic macular edema (DME).

                          Brand Name : EC-104

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 12, 2024

                          Lead Product(s) : Fluocinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Upon acquisition ANI will inherit Iluvien (fluocinolone acetonide), a drug used to treat diabetic macular oedema & recurrent non-infectious posterior uveitis in the US, Europe and Middle East.

                          Brand Name : Iluvien

                          Molecule Type : Small molecule

                          Upfront Cash : $381.0 million

                          June 24, 2024

                          Lead Product(s) : Fluocinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : ANI Pharmaceuticals Inc

                          Deal Size : $381.0 million

                          Deal Type : Acquisition

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : YUTIQ (fluocinolone acetonide) intravitreal implant 0.18mg is being evaluated in phase 4 clinical trials for the treatment of chronic non-infectious uveitis and related intraocular inflammation.

                          Brand Name : Yutiq

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 04, 2024

                          Lead Product(s) : Fluocinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The product ILUVIEN (fluocinolone acetonide) is a sustained release intravitreal implant injected into the back of the eye. ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to av...

                          Brand Name : Iluvien

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 24, 2023

                          Lead Product(s) : Fluocinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Through the divestment, Alimera will receive global rights to YUTIQ outside of China, Hong Kong, Taiwan, Macau and Southeast Asia. YUTIQ® (fluocinolone acetonide) is indicated for the treatment of chronic, non-infectious uveitis affecting the posterior ...

                          Brand Name : Yutiq

                          Molecule Type : Small molecule

                          Upfront Cash : $75.0 million

                          May 18, 2023

                          Lead Product(s) : Fluocinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Alimera Sciences

                          Deal Size : $82.5 million

                          Deal Type : Divestment

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the agreement, Alimera and Horus have agreed to increase the commercialization efforts for ILUVIEN (fluocinolone acetonide) for both diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in Euro...

                          Brand Name : Iluvien

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 03, 2023

                          Lead Product(s) : Fluocinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Alimera Sciences

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Iluvien (fluocinolone acetonide intravitreal implant) is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for 36 months, to reduce the recurrence of disease, enabling patients to maintain vision longer with fewer inje...

                          Brand Name : Iluvien

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 22, 2023

                          Lead Product(s) : Fluocinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : PALADIN phase 4 data demonstrate ILUVIEN (fluocinolone acetonide) patients experienced on average an increase in visual acuity, a significant decrease in retinal thickness and a predictable and manageable safety profile over 36 months.

                          Brand Name : Iluvien

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 06, 2022

                          Lead Product(s) : Fluocinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank